
Pharmacally
Duchenne
Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.
Latest in Duchenne
Health TidingsSarepta’s Duchenne Drugs AMONDYS 45 and VYONDYS 53 Advance Toward Full FDA ApprovalThe FDA has accepted supplemental NDAs for Sarepta’s AMONDYS 45 and VYONDYS 53, exon‑skipping therapies for Duchenne muscular dystrophy.Fact-Checked
Clinical TrialsREGENXBIO Completes RGX-202 Confirmatory Study Enrollment, Advances Duchenne Gene Therapy Toward FDA FilingREGENXBIO has completed dosing in the confirmatory study of RGX-202, an investigational gene therapy for Duchenne muscular dystrophy.Fact-Checked
Clinical TrialsREGENXBIO Delivers Positive Results for Duchenne Therapy RGX-202REGENXBIO announced positive topline data from the pivotal Phase III AFFINITY DUCHENNE trial of RGX-202 in Duchenne Muscular Dystrophy, demonstrating robust microdystrophin expression, functional improvement, and a manageable…Fact-Checked
Clinical TrialsEntrada Strengthens Its Duchenne Pipeline With Positive ENTR-601-44 Study ReadoutEntrada Therapeutics announced positive topline results from Cohort 1 of the Phase 1/2 ELEVATE-44-201 study evaluating ENTR-601-44 in Duchenne muscular dystrophy patients amenable to exon 44 skipping.Fact-Checked
Clinical TrialsCapricor Reports Phase 3 HOPE-3 Results for Deramiocel in DuchennePhase 3 HOPE-3 results presented at AAN 2026 show Deramiocel delivers meaningful functional benefit in Duchenne muscular dystrophy, supported by both clinical and real-world assessments, as FDA review…Fact-Checked
Explore more
Health TidingsIndustry, pipeline and company news.
RegulatoryApprovals, policy and agency decisions.
ResearchPeer-reviewed studies and scientific breakthroughs.
Drug FinderLook up any drug: uses, dosing and safety.
From the HistoryLandmark moments in pharmaceutical history.
LatestEvery new story, as soon as it is published.